Lantern Pharma发布Lp-184一期a阶段的积极结果,显示在重度治疗的晚期癌症患者中具备持久的疾病控制。
Lantern Pharma发布Lp-184一期a阶段的积极结果,显示在重度治疗的晚期癌症患者中具备持久的疾病控制。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.